endometriosis - opportunity analysis and … › product › sample-8021847.pdfendometriosis -...
TRANSCRIPT
REFERENCE CODE GDHC015POA | PUBLICAT ION DATE DECEMBER 2013
ENDOMETRIOSIS - OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Endometriosis – Opportunity Analysis and Forecasts to 2017 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Executive Summary
The table below presents the key metrics for
endometriosis therapeutics in the six major
pharmaceutical markets covered in this report (US,
France, Germany, Italy, Spain, and UK) during the
forecast period from 2012–2017. For the purposes
of this report, the endometriosis market consists of
drugs commonly prescribed to patients with a
diagnosis of endometriosis confirmed by
laparoscopy. While certain classes of drugs
commonly used off label — namely, combined oral
contraceptives (COCs) — which contain both an
estrogen and a progestin — are included in this
forecast, others are not. For example, non-
steroidal anti-inflammatory drugs (NSAIDs) and
other analgesics are deliberately omitted from this
analysis.
Endometriosis Therapeutics: Key Metrics in Six Major Markets (6MM), 2012–2017
2012 Patient Population 6MM
Prevalent population (ages 15–19 Years) 5.8 million
Prevalent population (ages 20–49 Years) 8.3 million
Treated population*
2012 Market Sales
US 1.64 billion
5EU 71.1 million
Total 1.71 billion
Key Events (2012–2017) Level of Impact
Lupron (leuprolide acetate) patent expiry in the US and EU 2014 ↓↓
Elagolix launch in the US and EU – 2016 ↑↑
2017 Market Sales
US $1.67 billion
5EU $68.48 million
Total $1.74 billion Source: GlobalData *Excludes patients managed only via NSAIDs or surgery alone. 6MM = US and 5EU (France, Germany, Italy, Spain, and UK)
Global Endometriosis Therapeutics Market Expected to Decrease at a Compound Annual Growth Rate of 0.19% During 2012–2017
GlobalData estimates that the global endometriosis
therapeutics market in the 6MM was valued at
$1.88 billion in 2012. The market was largely
dominated by the US, with sales of $1.1 billion.
Combined sales in the 5EU were estimated at
$137.6m. By 2017, GlobalData forecasts that
global sales of endometriosis therapeutics will
decrease slowly to $1.66 billion at a Compound
Annual Growth Rate (CAGR) of 0.19%.
By the end of the forecast period in 2017,
GlobalData foresees that market growth will remain
driven by the US, with marginal changes in the
5EU share by 2017. The patent expiry of Lupron
(leuprolide acetate) in 2014 is expected to have a
negative effect on this market. However, since it is
a sterile injectable drug, GlobalData has tempered
the potential effect of this event, as manufacturers
may face barriers when attempting to create
generic equivalents.
The figure below illustrates the global sales for
endometriosis therapeutics by region during the
forecast period.
Endometriosis – Opportunity Analysis and Forecasts to 2017 3 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Executive Summary
Global Sales for Endometriosis Therapeutics by Region, 2012–2017
96%
4%2012 Total:$1.71bn
US
5EU
96%
4% 2017 Total:$1.75bn
US
5EU
Source: GlobalData
Nonetheless, this waning market will regain
momentum upon the expected launch of elagolix, a
first-in-class oral gonadotropin-releasing hormone
(GnRH) antagonist, in the US and 5EU in 2016.
Since price is a primary attribute driving therapy
choice in this market, new entrants such as
elagolix will have little potential to steal share from
low-cost therapies such as OCs, NSAIDs, and
progestins.
Endometriosis Market Plagued by High Unmet Need
Patients with endometriosis have significant unmet
needs due to the lack of approved treatment
options that have both continuous efficacy and a
favorable long-term safety profiles. Laparoscopic
surgery, either alone or in combination with
hormone therapy (HT), is typically the first
treatment choice for physicians. However, the
methods of treating the condition, have been
largely haphazard. As a result, women often
undergo numerous rounds of surgery and try
several medical approaches before finding relief.
Even after finding a suitable solution, patients can
expect a high rate of recurrence. The current
approved treatment options for endometriosis
include GnRH agonists, progestins, and
androgens, each of which has its own safety and
efficacy limitations. Although the use of GnRH
agonists has increased in the past decade, the
duration of therapy is typically limited to six months
due to hypoestrogenic side effects, such as hot
flashes, and significant bone mineral density
(BMD) loss. Moreover, these drugs come with
hefty price tags, which further stifles their appeal
for long-term use. NSAIDs and COCs are
commonly prescribed off label for confirmed and
suspected cases of endometriosis, although their
efficacy in this indication has not been validated via
randomized clinical trials. Because of the intrinsic
limitations of the currently available therapies,
innovative drugs with novel mechanisms of action
are required in order to address the unmet needs
of endometriosis patients.
Endometriosis – Opportunity Analysis and Forecasts to 2017 4 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Executive Summary
GnRH Antagonists will Replace GnRH Agonists, but Their High Price Will Limit Further Adoption
GnRH antagonists dominate the late-stage pipeline
for endometriosis therapeutics, with three agents
being in Phase II or Phase III (Abott’s elagolix,
Takeda’s relugolix, and Astellas’ ASP-1707).
Elagolix, which is in Phase III, promises to be the
first oral GnRH antagonist approved for
endometriosis. This class of therapies has several
key advantages over the currently marketed GnRH
agonists. In terms of safety and tolerability, elagolix
avoids the detrimental hypoestrogenic side effects
seen with GnRH agonists such as Lupron and
Zoladex (goserelin acetate). According to key
opinion leaders (KOLs) interviewed by GlobalData,
an oral formulation will be a welcome addition to
the field because it provides doctors with increased
control over dosing and allows for the immediate
cessation of therapy, if necessary. Therefore,
GlobalData believes that GnRH antagonists will
rapidly replace the GnRH agonist market segment.
Based on their improved efficacy and safety profile,
GnRH antagonists like elagolix are likely to be
priced at a premium over GnRH agonists such as
Lupron. Due to the low cost of progestins, COC’s,
and NSAIDs, GlobalData believes that the GnRH
antagonists are unlikely to take substantial market
share away from these drugs. Like GnRH agonists,
GnRH antagonists can only be administered for a
short period of time, which will restrict their use to
late-line therapy and sicker patients. Until more
long-term safety data are gathered, and there is
evidence that GnRH agonists can be used safely
for a longer treatment duration, GlobalData
believes that GnRH antagonists will only serve as
follow-up drugs to GnRH agonists.
The figure below provides a competitive
assessment of the marketed and late-stage
pipeline agents in endometriosis therapeutics
during the forecast period.
Competitive Assessment of Marketed and Late-Stage Pipeline Agents in Endometriosis Therapeutics, 2012–2017
Lupron
Elagolix
TAK-385
ASP-1707
Depo Sub-Q Provera
COC's
2
4
2 4
Com
mer
cial
Sco
re
Clinical Score
Source: GlobalData
Opportunity Remains High for Innovative Therapies
Since none of the late-stage drug candidates are
meant to address the high unmet need in the
endometriosis therapeutics market, the
management of the disease is not likely to evolve
during the forecast period, and opportunities in the
market will remain particularly high. Whether it is
for safer drugs or drugs that demonstrate efficacy
in mild or severe patients through robust clinical
trials, the market is crying for new therapies.
Ultimately, since all of the marketed, off-label, and
pipeline drugs have little impact in curbing the
disease progression, a high rate of recurrence is
Endometriosis – Opportunity Analysis and Forecasts to 2017 5 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Executive Summary
expected upon cessation of therapy. Therefore,
large opportunities will remain for safe, efficacious
therapies that target the root cause of the
condition. Non-hormonal strategies, in particular,
are promising, including immune modulators,
peroxisome proliferator-activated receptor (PPAR)
agonists, tumor necrosis factor-alpha (TNF-alpha)
inhibitors, and antiangiogenic agents. In
conclusion, a much better understanding of the
underlying pathology of this condition will be
required in order for a novel therapy to achieve
considerable success in the endometriosis market.
What Do Physicians Think?
The consensus among the KOLs interviewed for
this report is that endometriosis patients have
significant unmet needs due to the lack of safe,
efficacious, long-term therapies. Furthermore,
significant gaps in the current understanding of the
underlying disease pathology were flagged as a
hurdle plaguing endometriosis therapy
development. Although the KOLs are optimistic
about the potential approval of first-in-class
therapy, elagolix, they still foresee that unmet
needs will persist. One common concern about
GnRH antagonist therapy is that it continues to
approach the treatment of endometriosis via
hormonal pathways. A key limitation is that these
drugs do not target the underlying cause of the
disease, which means that recurrence is expected
to occur once a woman stops therapy. Since
endometriosis starts as early as adolescence and
can be expected to persist until menopause, any
drug that only addresses the symptoms of
endometriosis will translate into decades of
disease management, rather than resolution of the
condition.
One key weakness of the hormonal regimens used
to treat endometriosis is that they prevent
conception. Given the fact that the majority of
women who suffer from endometriosis are of
childbearing age, there is a considerable unmet
need for a novel therapy that allows for
continuation of the normal menstrual cycle and
provides for the possibility of pregnancy during
treatment. Given the estrogen-dependent nature of
endometriosis, the current therapies target the
condition by disrupting hormonal pathways which
play a key role in fertility. Although some novel
therapeutic classes that are under development
have shown promising efficacy data, many of these
approaches have side effects that would
contraindicate their use in women looking to
conceive.
“I am sure that GnRH antagonists will be effective.
The problem is that women will have recurrences
[of endometriosis] once they will discontinue the
drug.”
EU KOL, October 2013
“Approaching the disease from an inflammatory
standpoint would be an innovative approach that I
would be interested in seeing.”
EU KOL, October 2013
Endometriosis – Opportunity Analysis and Forecasts to 2017 6 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Executive Summary
“We don’t know very much about the real
mechanism underlying the generation of pain in
endometriosis.”
US KOL, October 2013
“I believe GnRH antagonists will be yet another
class [of drugs] that would be useful in the
management of endometriosis.”
US KOL, October 2013
“The oral formulation of GnRH antagonists will
certainly provide advantages over the injectable
GnRH agonists.”
US KOL, October 2013
Endometriosis – Opportunity Analysis and Forecasts to 2017 7 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
1 Table of Contents
1 Table of Contents ....................................................................................................................... 7
1.1 List of Tables .................................................................................................................... 12
1.2 List of Figures ................................................................................................................... 14
2 Introduction ............................................................................................................................... 15
2.1 Catalyst ............................................................................................................................. 15
2.2 Related Reports ................................................................................................................ 15
3 Disease Overview ..................................................................................................................... 16
3.1 Etiology and Pathophysiology ........................................................................................... 16
3.2 Etiology ............................................................................................................................. 18
3.3 Pathophysiology ................................................................................................................ 18
3.4 Clinical Prognosis ............................................................................................................. 21
3.5 Quality of Life .................................................................................................................... 21
3.6 Symptoms and Diagnosis ................................................................................................. 22
4 Epidemiology ............................................................................................................................ 23
4.1 Risk Factors and Comorbidities ........................................................................................ 23
4.1.1 Family history is a strong predictor for the risk of endometriosis .................................... 23
Late age at menarche protects women from developing endometriosis. ....................................... 24
4.1.2 Higher parity decreases the risk for endometriosis ........................................................ 25
4.2 Global Trends ................................................................................................................... 27
4.2.1 US ................................................................................................................................. 28
4.2.2 5EU ............................................................................................................................... 28
4.2.3 Forecast Methodology ................................................................................................... 29
4.2.4 Sources Used................................................................................................................ 31
4.2.5 Sources Not Used ......................................................................................................... 33
4.2.6 Forecast Assumptions and Methods ............................................................................. 33
4.3 Epidemiological Forecast for Endometriosis (2012–2022) ................................................. 36
Endometriosis – Opportunity Analysis and Forecasts to 2017 8 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
4.3.1 Diagnosed Prevalent Cases of Endometriosis ............................................................... 36
4.3.2 Age-Specific Prevalent Cases of Endometriosis ............................................................ 37
4.3.3 Age-Standardized Diagnosed Prevalence of Endometriosis .......................................... 39
4.3.4 Diagnosed Prevalent Cases of Endometriosis by Stage ................................................ 40
4.4 Discussion ........................................................................................................................ 42
4.4.1 Epidemiological Forecast Insight ................................................................................... 42
4.4.2 Limitations of the Analysis ............................................................................................. 43
4.4.3 Strengths of the Analysis ............................................................................................... 44
5 Current Treatment Options ....................................................................................................... 46
5.1 Overview ........................................................................................................................... 46
5.2 Product Profiles – Major Brands ........................................................................................ 49
5.2.1 Zoladex (goserelin acetate) ........................................................................................... 49
5.2.2 Lupron (leuprolide acetate depot) .................................................................................. 52
5.2.3 Synarel (nafarelin nasal spray) ...................................................................................... 54
5.2.4 Visanne (dienogest) ...................................................................................................... 57
5.2.5 Depo-SubQ Provera 104 (medroxyprogesterone injection) ........................................... 60
5.2.6 Danazol (Danocrine) ..................................................................................................... 62
5.2.7 Off-Label Treatment: Combined Oral Contraceptives, Progestins, and NSAIDs ............ 64
6 Unmet Needs Assessment and Opportunity Analysis ............................................................... 68
6.1 Overview ........................................................................................................................... 68
6.2 Unmet Needs Analysis ...................................................................................................... 69
6.2.1 Unmet Need: Non-Invasive Diagnostics ........................................................................ 69
6.2.2 Unmet Need: Non-Hormonal Therapies ........................................................................ 70
6.2.3 Unmet Need: Better Pain Management ......................................................................... 70
6.2.4 Unmet Need: Better Understanding of the Disease Pathology to Prevent Recurrence .. 71
6.2.5 Unmet Need: Identification of Biomarkers ..................................................................... 72
6.2.6 Unmet Need: Transparency in Clinical Trials ................................................................. 72
Endometriosis – Opportunity Analysis and Forecasts to 2017 9 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
6.3 Opportunity Analysis ......................................................................................................... 73
6.3.1 Opportunity: Biomarkers Identification ........................................................................... 73
6.3.2 Opportunity: Treatment Options for Adolescents ........................................................... 74
6.3.3 Opportunity: Drugs Targeting Pain Pathways ................................................................ 74
6.3.4 Opportunity: Novel Targets............................................................................................ 75
6.3.5 Opportunity: Efficacious Treatments Suitable for Long-Term Use ................................. 75
6.4 Research and Development Strategies ............................................................................. 76
6.4.1 Overview ....................................................................................................................... 76
6.4.2 The Race for the Development of GnRH Antagonists.................................................... 77
6.4.3 Alliances and In-Licensing Strategies ............................................................................ 77
6.4.4 Maximizing Return-on-Investment by Targeting Secondary indications ......................... 78
6.5 Clinical Trial Design .......................................................................................................... 79
6.5.1 Overview ....................................................................................................................... 79
6.5.2 Defining Efficacy in Endometriosis Clinical Trials .......................................................... 79
6.5.3 Future Trends in Endometriosis Clinical Trial Design .................................................... 84
7 Pipeline Assessment................................................................................................................. 85
7.1 Overview ........................................................................................................................... 85
7.2 Promising Drugs in Development ...................................................................................... 86
7.2.1 Elagolix (ABT-602) ........................................................................................................ 87
7.2.2 Relugolix (TAK-385) ...................................................................................................... 91
7.2.3 ASP-1707 ...................................................................................................................... 93
7.3 Innovative Early-Stage Approaches .................................................................................. 95
7.3.1 Overview ....................................................................................................................... 95
7.3.2 Anti-Inflammatory Approaches ...................................................................................... 97
7.3.3 Cellular Adhesion .......................................................................................................... 98
7.3.4 Angiogenesis Endometriotic Implants ............................................................................ 98
7.3.5 Selective Progesterone Receptor Modulators................................................................ 99
Endometriosis – Opportunity Analysis and Forecasts to 2017 10 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
7.3.6 Aromatase Inhibitors ................................................................................................... 100
8 Pipeline Valuation Analysis ..................................................................................................... 101
8.1 Overview ......................................................................................................................... 101
8.2 Clinical Benchmarking of Key Pipeline Drugs .................................................................. 101
8.3 Commercial Benchmarking of Key Pipeline Drugs .......................................................... 105
8.4 Competitive Assessment ................................................................................................. 106
8.5 Top-Line, Five-Year Forecasts ........................................................................................ 107
8.5.1 Overview ..................................................................................................................... 107
8.5.2 US ............................................................................................................................... 110
8.5.3 5EU ............................................................................................................................. 111
9 Appendix................................................................................................................................. 113
9.1 Bibliography .................................................................................................................... 113
9.2 Abbreviations .................................................................................................................. 124
9.3 Methodology ................................................................................................................... 127
9.4 Forecasting Methodology ................................................................................................ 127
9.4.1 Diagnosed Endometriosis Patients .............................................................................. 128
9.4.2 Percent Drug Treated Patients .................................................................................... 129
9.4.3 Drugs Included in Each Therapeutic Class .................................................................. 130
9.4.4 Launch and Patent Expiry Dates ................................................................................. 130
9.4.5 General Pricing Assumptions ...................................................................................... 131
9.4.6 Individual Drug Assumptions ....................................................................................... 131
9.4.7 Generic Erosion .......................................................................................................... 134
9.4.8 Pricing of Pipeline Agents............................................................................................ 134
9.5 Physicians and Specialists Included in This Study .......................................................... 135
9.6 About the Authors ........................................................................................................... 136
9.6.1 Author ......................................................................................................................... 136
9.6.2 Epidemiologist ............................................................................................................. 136
Endometriosis – Opportunity Analysis and Forecasts to 2017 11 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
9.6.3 Global Director of Epidemiology and Health Policy ...................................................... 137
9.6.4 Global Head of Healthcare .......................................................................................... 137
9.7 About GlobalData ............................................................................................................ 138
9.8 Disclaimer ....................................................................................................................... 138
Endometriosis – Opportunity Analysis and Forecasts to 2017 12 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
1.1 List of Tables
Table 1: ICD-9-CM Codes for Endometriosis and Pelvic Pain .................................................................... 17
Table 2: Stages of Endometriosis .............................................................................................................. 19
Table 3: Symptoms of Endometriosis ........................................................................................................ 22
Table 4: Risk Factors for Endometriosis .................................................................................................... 23
Table 5: Epidemiological Sources for the Diagnosed Prevalence and Stages of Endometriosis ................. 30
Table 6: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15–49 Years, N, 2012–2022.............. 36
Table 7: 6MM, Diagnosed Prevalent Cases of Endometriosis, by Age, N, Row (%), 2012 .......................... 38
Table 8: Leading Branded Treatments for Endometriosis .......................................................................... 48
Table 9: Product Profile – Zoladex ............................................................................................................ 50
Table 10: SWOT Analysis – Zoladex ........................................................................................................... 51
Table 11: Product Profile – Lupron .............................................................................................................. 52
Table 12: SWOT Analysis – Lupron ............................................................................................................ 54
Table 13: Product Profile – Synarel ............................................................................................................. 55
Table 14: SWOT Analysis – Synarel ........................................................................................................... 56
Table 15: Product Profile – Visanne ............................................................................................................ 57
Table 16: SWOT Analysis – Visanne........................................................................................................... 59
Table 17: Product Profile – Depo-SubQ Provera 104 .................................................................................. 60
Table 18: SWOT Analysis – Depo-SubQ Provera 104 ................................................................................. 62
Table 19: Product Profile – Danazol ............................................................................................................ 63
Table 20: SWOT Analysis – Danazol .......................................................................................................... 64
Table 21: Branded Hormonal Contraceptives Commonly Used Off Label for Endometriosis ........................ 65
Table 22: Progestins Commonly Used Off Label for Endometriosis ............................................................. 66
Table 23: Overall Unmet Needs – Current Level of Attainment .................................................................... 69
Endometriosis – Opportunity Analysis and Forecasts to 2017 13 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Table 24: Common Primary and Secondary Outcome Measures in Endometriosis Clinical Trials ................ 80
Table 25: Design of the Most Relevant Current Phase II and III Clinical Trials in Endometriosis................... 82
Table 26: Endometriosis – Late-Stage Pipeline, 2012 ................................................................................. 86
Table 27: Product Profile – Elagolix............................................................................................................. 88
Table 28: SWOT Analysis – Elagolix ........................................................................................................... 90
Table 29: Product Profile – Relugolix .......................................................................................................... 92
Table 30: SWOT Analysis – Relugolix ......................................................................................................... 93
Table 31: Product Profile – ASP-1707 ......................................................................................................... 94
Table 32: SWOT Analysis – ASP-1017 ....................................................................................................... 95
Table 33: Early-Stage Pipeline Products for Endometriosis ......................................................................... 96
Table 34: Clinical Benchmarking of Key Pipeline Drugs for Endometriosis ................................................. 102
Table 35: Commercial Benchmarking of Key Pipeline Drugs for Endometriosis ......................................... 105
Table 36: Top Line Sales Forecasts ($) for Endometriosis, 2012–2017 ..................................................... 108
Table 37: Endometriosis Therapeutics Market – Drivers and Barriers, 2012 – 2017 .................................. 110
Table 38: Key Events Influencing Sales for Endometriosis, 2012–2017 ..................................................... 110
Table 39: Key Launch Dates ..................................................................................................................... 130
Table 40: Key Patent Expiries ................................................................................................................... 130
Endometriosis – Opportunity Analysis and Forecasts to 2017 14 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
1.2 List of Figures
Figure 1: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15–49 Years, N, 2012–2022.............. 37
Figure 2: 6MM, Diagnosed Prevalent Cases of Endometriosis, by Age, N, 2012 ......................................... 38
Figure 3: 6MM, Age-Standardized Diagnosed Prevalence (%) of Endometriosis, Ages 15–49 Years, 2012 . 40
Figure 4: 6MM, Diagnosed Prevalent Cases of Endometriosis by Stage, Ages 15–49 Years, 2012 ............. 41
Figure 5: Endometriosis Pipeline by Phase, 2012–2017 ............................................................................. 86
Figure 6: Advantages of GnRH Antagonists Over GnRH Agonists .............................................................. 87
Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in Endometriosis Therapeutics, 2012–
2017.......................................................................................................................................... 107
Figure 8: Global Sales for Endometriosis Therapeutics by Region, 2012–2017 ......................................... 109
Endometriosis – Opportunity Analysis and Forecasts to 2017 15 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
Introduction
2 Introduction
2.1 Catalyst
The endometriosis therapeutics market has been in need of innovative therapies for quite a while.
Competition in this market has historically been weak due to the lack of approved products.
Hormonal therapies have dominated this market, yet the currently approved drugs leave much to
be desired in terms of their risk-benefit profiles and long-term efficacy. The endometriosis
therapeutics market is expected to experience a flurry of changes over the next five years.
Although the market-leading gonadotropin-releasing hormone (GnRH) agonist, Lupron (leuprolide
acetate), will lose patent protection in 2014, this change will be offset by the launch of AbbVie and
Neurocrine’s first-in-class oral GnRH antagonist, elagolix. The entry of elagolix will provide a much-
needed jolt to this market. In fact, this product will be the first major innovation in this indication in
many years. Being orally active is a major benefit of elagolix, which will potentially offer several
advantages over the incumbent injectable GnRH agonists. The GnRH antagonist mechanism of
action allows for the rapid onset of estrogen suppression, without the hormonal flare effect seen
with the GnRH agonists. Furthermore, the deleterious BMD loss seen with the injectable GnRH
agonists is not seen with the GnRH antagonists. Ultimately, elagolix’s oral route of administration
will be a welcome addition to the therapeutic paradigm that will give doctors more control over
dosing and will allow for the titration of circulating estrogen levels. By allowing for modulation of the
level of ovarian suppression, elagolix will be a customizable solution, with increased safety over the
currently approved drugs. Elagolix’s major commercial attribute will be its potential to tap into a
larger patient pool than drugs such as the GnRH agonists, Lupron and Zoladex (gosarelin acetate).
2.2 Related Reports
GlobalData (2013). EpiCast Report: Endometriosis – Epidemiology Forecast to 2022,
PHARMAEPIA35167.
Endometriosis – Opportunity Analysis and Forecasts to 2017 137 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Appendix
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
9.6.3 Global Director of Epidemiology and Health Policy
Franka des Vignes, PhD, currently serves as the Global Director of Epidemiology and Health
Policy at GlobalData in New York City, where her primary responsibilities include managing the
production and quality of the epidemiology reports and forecast models, improving the
epidemiology database, liaising with clients to identify their satisfaction with the existing
epidemiology offerings, prioritizing critical unmet needs, and supporting GlobalData teams with
consulting opportunities. Prior to joining GlobalData, Franka worked for several years in the public
sector to implement and manage several large projects leading to successful disease surveillance
programs in the United States. Her experience includes analyzing epidemiological trends,
assessing clinical trials, and performing pharmaceutical market forecasting in the private sector. In
the nonprofit sector, she served as the Deputy Director of a Washington DC-based organization
focused on health policy regarding HIV/AIDS. In the international arena, she has advised national
Ministries of Health and has worked for international health organizations such as
CAREC/PAHO/WHO to provide technical assistance to governments with health systems’
strengthening, patient population databases, and the assessment of surveillance systems in more
than 20 countries in the Caribbean and Latin America. Franka holds a Master of Science in
Microbiology and a PhD in Epidemiology and Public Health from Yale University.
9.6.4 Global Head of Healthcare
Bonnie Bain, PhD, is Global Head of Healthcare for GlobalData in Boston, managing the Medical
and Pharmaceutical arms of the business. Prior to this role, she was Vice President and Global
Research & Analysis Director for Informa, where she oversaw the global strategy and operations
for Datamonitor Healthcare’s syndicated business. Bonnie has over 15 years of experience in the
healthcare sector and a proven track record of developing innovative solutions on both the client
and vendor sides of the business. Prior to joining Informa, she was Director of Product
Development at Wood Mackenzie, where she oversaw the development and management of two
product lines. Bonnie also worked for several years at Decision Resources as an Analyst and
Project Manager. On the client side of the industry, she worked for several years as a Senior
Manager in Marketing Strategy and Analytics at Boston Scientific, where her work contributed to
the successful commercialization of the first-ever Access and Visualization Platform at the
company. She has a PhD in Biochemistry and Molecular Biology from Purdue University, and was
a postdoctoral fellow in molecular pharmacology at the University of Miami School of Medicine.
Endometriosis – Opportunity Analysis and Forecasts to 2017 138 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Appendix
ENDOMETRIOSIS – OPPORTUNITY ANALYSIS AND FORECASTS TO 2017
9.7 About GlobalData
GlobalData is a leading global provider of business intelligence in the healthcare industry.
GlobalData provides its clients with up-to-date information and analysis on the latest developments
in drug research, disease analysis, and clinical research and development. Our integrated business
intelligence solutions include a range of interactive online databases, analytical tools, reports, and
forecasts. Our analysis is supported by a 24/7 client support and analyst team.
GlobalData has offices in New York, Boston, London, India, and Singapore.
9.8 Disclaimer
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any
form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior
permission of the publisher, GlobalData.